Japan · Advertising framework
Influencer marketing for OTC medicines in Japan
General market orientation, not campaign clearance. Research scope and dates
Product and service rules
Keep claims within the permitted scope
Regulator guidance
Check the approved efficacy, use and dosage and the applicable precautions. The advertising standards reject exaggerated or guaranteed efficacy and safety representations. Public availability does not permit claims outside the product’s approved scope.
Sources: Standards for Fair Advertising of Pharmaceuticals and related products, 2017
Check the professional-recommendation restriction
Regulator guidance
The advertising standards restrict specified professional and institutional recommendations. Check the exact endorser and product before commissioning an expert testimonial.
Sources: Standards for Fair Advertising of Pharmaceuticals and related products, 2017
Check approval before promoting a product’s name or performance
Legal requirement — paraphrased
Applies when: The product falls within the approval/certification categories specified by Article 68.
MHLW’s PMD Act summary identifies Article 68 as a prohibition on advertising the name, manufacture, efficacy, effect or performance of specified medicines and devices before required approval or certification. Describing an offer as pre-launch does not itself establish an exemption.
Determine the Japanese regulatory route for the exact product or software function before publishing a campaign. This module does not classify every health app as a medical device.
Sources: MHLW: advertising regulation under the PMD Act · PMD Act Article 68 as reproduced by MHLW
Channel rules
Check the complete consumer-facing message
Regulator guidance
The misleading-representations regime covers goods and services, including misleading impressions about quality or price advantages. Review the full presentation and offer conditions. A truthful individual detail does not justify a deceptive overall claim.
Sources: Establishing Trusted Representation
Advertiser-directed content must be recognisable as advertising
Regulator guidance
CAA’s stealth-marketing rule addresses a supplying advertiser involved in determining a representation whose commercial nature consumers cannot recognise. Assess the brand’s role in the content and the overall presentation, including commissioned posts and reviews.
An influencer acting only as the commissioned publisher is generally not the regulated advertiser under this particular designation; CAA identifies joint supply of the product as an exception. This does not exempt the content from product-advertising law or other duties.
Sources: Stealth marketing regulation from 1 October 2023; CAA — Stealth marketing questions and answers · CAA stealth-marketing FAQ Q1
Brief the creator on the permitted message
Editorial recommendation
Check whether endorsements are permitted for the selected offer before contracting a creator. Record payments, gifts and affiliate links; specify the required advertising identification, approved claims, editing controls and takedown process.
Campaign workflow
OTC Medicines: prepare the review
Editorial recommendation
Confirm the exact product qualifies for consumer advertising in this country. Match each indication, dosage and safety statement to the current local product information. Obtain the applicable warning wording and format rules before buying space.
Keep a traceable campaign decision
Editorial recommendation
Keep one review record linking the offer, local market status, claim evidence, exact creative, media settings and any regulatory or professional clearance. Record who checked each condition. Reopen the review when the offer, claim, source rule or execution changes.
Pre-publication checklist
- Confirm the exact product qualifies for consumer advertising in this country.
- Match each indication, dosage and safety statement to the current local product information.
- Obtain the applicable warning wording and format rules before buying space.
- Record product or provider eligibility before approving claims.
- Archive the final creative and its evidence, permissions and review decisions.
- Assign an owner for source updates, complaints and prompt withdrawal of inaccurate material.
Scope and unresolved questions
- March 2026 sixth-edition medical advertising examples, website exemption conditions and FFC transitions have been checked. Remaining checks concern prefectural implementation, practitioner-specific and pharmacy requirements, actual product notifications and treatment disclosures, personal-information processing and each messaging technology. This pack does not supply every Japanese mandatory warning text.
- This national baseline does not review every broadcaster rule, platform policy, regional licensing condition, promotion mechanic or data-transfer arrangement. No format-specific warning dimensions or durations should be inferred where none are supplied.
Research scope, introduction and dates
For OTC medicines through influencer collaborations in Japan, confirm the advertising status of the exact product. This framework connects the locally permitted uses with the information, warnings and execution checks relevant to the selected channel.
Creator selection and commercial disclosure are only part of an influencer review. Examine the person's role, the spoken and visual claims, supplied benefits and the final publication together; a personal experience can still communicate a regulated claim.
General market orientation, not legal, regulatory or medical advice, a complete compliance plan or clearance of an advertisement. Actual requirements depend on the specific offer and campaign.
How to use this national baseline
Editorial overview
This framework combines researched national rules with editorial review steps. Japanese product and medical-service advertising baseline; local and product-specific implementation requires review. A visible channel workflow does not establish that the selected product or service may be advertised there. Read the category restrictions first.
The review date identifies when the cited provisions or regulator excerpts were checked. It does not mean that every local rule, exception, professional standard or platform policy has been reviewed.
Sources
- Standards for Fair Advertising of Pharmaceuticals and related products, 2017
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
- Establishing Trusted Representation
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
- Stealth marketing regulation from 1 October 2023
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
- CAA — Stealth marketing questions and answers
Targeted review on 25 October 2026. This date does not certify the currency of other sources or resolve local and campaign-specific requirements.
- MHLW: advertising regulation under the PMD Act
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
From framework to action
Local expertise in Japan
Find support with medical and health marketing, marketing and sales advice, or organizing your business and coordinating projects in Japan.
Medical & health marketing
No partners listed in this category yet.
Marketing & sales advisory
No partners listed in this category yet.
Business & project coordination
No partners listed in this category yet.
Join the local partner directory
Would you like your company to be listed?
Talk to us about the terms of a listing. Leave your details and we will get in touch.